20464 Federal Register / Vol. 87, No. 67 / Thursday, April 7, 2022 / Notices 

Commission disclosing changes in its 

membership. The notifications were 

filed for the purpose of extending the 

Act’s provisions limiting the recovery of 

antitrust plaintiffs to actual damages 

under specified circumstances. 

Specifically, Semalytix GmbH, 

Bielefeld, GERMANY; Schrodinger, 

Portland, NY; SAGE Therapeutics, 

Cambridge, MA; Rapid Novor, Waterloo, 

CANADA; Matador Japan KK, Nagano, 

JAPAN; Claire Bellamy (individual 

member), Leicestershire, UNITED 

KINGDOM; Chitrita Goswami 

(individual member), New Delhi, 

INDIA; Eurofins Discovery, St. Charles, 

MO; Centre for Process Innovation, 

Wilton, UNITED KINGDOM; and 

Artificial Inc., Palo Alto, CA have been 

added as parties to this venture. 

Also, WorldQuant Predictive, New 

York, NY; telic, New York, NY; 

Synthace Ltd, London, UNITED 

KINGDOM; Sapio Sciences, Baltimore, 

MD; PHEMI Systems Corp., Vancouver, 

CANADA; Mcule, Budapest, 

HUNGARY; GenAIz, Montreal, 

CANADA; and Apheris AI GmbH, 

Berlin, GERMANY have withdrawn as 

parties to this venture. 

No other changes have been made in 

either the membership or planned 

activity of the group research project. 

Membership in this group research 

project remains open, and Pistoia 

Alliance, Inc. intends to file additional 

written notifications disclosing all 

changes in membership. 

On May 28, 2009, Pistoia Alliance, 

Inc. filed its original notification 

pursuant to Section 6(a) of the Act. The 

Department of Justice published a notice 

in the Federal Register pursuant to 

Section 6(b) of the Act on July 15, 2009 

(74 FR 34364). 

The last notification was filed with 

the Department on September 12, 2021. 

A notice was published in the Federal 

Register pursuant to Section 6(b) of the 

Act on October 5, 2021 (86 FR 55002). 

Suzanne Morris, 

Chief, Premerger and Division Statistics, 

Antitrust Division. 

[FR Doc. 2022–07339 Filed 4–6–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–988] 

Bulk Manufacturer of Controlled 

Substances Application: Purisys, LLC 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Purisys, LLC. has applied to 

be registered as a bulk manufacturer of 

basic class(es) of controlled 

substance(s). Refer to SUPPLEMENTAL

INFORMATION listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before June 6, 2022. Such persons 

may also file a written request for a 

hearing on the application on or before 

June 6, 2022. 

ADDRESSES: The Drug Enforcement 

Administration requires that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on January 21, 2022, 1550 

Olympic Drive, Athens, Georgia 30601– 

1602, applied to be registered as a bulk 

manufacturer of the following basic 

class(es) of controlled substance(s): 

Controlled substance Drug 

code Schedule 

Cathinone .................................. 1235 I 

Gamma Hydroxybutyric Acid .... 2010 I 

Lysergic acid diethylamide ....... 7315 I 

Marihuana Extract ..................... 7350 I 

Marihuana ................................. 7360 I 

Tetrahydrocannabinols ............. 7370 I 

2,5-Dimethoxyamphetamine ..... 7396 I 

3,4-Methylenedioxy 

amphetamine. 

7400 I 

5-Methoxy-3,4-methylenedioxy 

amphetamine.

7401 I 

3,4-Methylenedioxy 

methamphetamine. 

7405 I 

5-Methoxy-N-N-dimethyl 

tryptamine. 

7431 I 

Diethyltryptamine ...................... 7434 I 

Dimethyltryptamine ................... 7435 I 

Psilocybin .................................. 7437 I 

Psilocyn ..................................... 7438 I 

Codeine-N-oxide ....................... 9053 I 

Dihydromorphine ....................... 9145 I 

Hydromorphinol ......................... 9301 I 

Morphine-N-oxide ..................... 9307 I 

Normorphine ............................. 9313 I 

Norlevorphanol .......................... 9634 I 

Codeine ..................................... 9050 II 

Dihydrocodeine ......................... 9120 II 

Oxycodone ................................ 9143 II 

Hydromorphone ........................ 9150 II 

Controlled substance Drug 

code Schedule 

Hydrocodone ............................. 9193 II 

Levorphanol .............................. 9220 II 

Morphine ................................... 9300 II 

Oripavine ................................... 9330 II 

Thebaine ................................... 9333 II 

Opium tincture .......................... 9630 II 

Opium, powdered ..................... 9639 II 

Opium, granulated .................... 9640 II 

Oxymorphone ........................... 9652 II 

Noroxymorphone ...................... 9668 II 

Alfentanil ................................... 9737 II 

Sufentanil .................................. 9740 II 

Carfentanil ................................. 9743 II 

Tapentadol ................................ 9780 II 

Fentanyl .................................... 9801 II 

The company plans to bulk 

manufacture the listed controlled 

substances for internal use 

intermediates or for sale to its 

customers. The company plans to 

manufacture the above-listed controlled 

substances as clinical trial and starting 

materials to make compounds for 

distribution to its customers. No other 

activities for these drug codes are 

authorized for this registration. 

Matthew J. Strait, 

Deputy Assistant Administrator. 

[FR Doc. 2022–07368 Filed 4–6–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

[OMB 1140–0092] 

Agency Information Collection 

Activities; Proposed eCollection of 

eComments Requested; Voluntary 

Magazine Questionnaire for Agencies/ 

Entities That Store Explosive Materials 

AGENCY: Bureau of Alcohol, Tobacco, 

Firearms and Explosives, Department of 

Justice. 

ACTION: 60-Day notice. 

SUMMARY: The Bureau of Alcohol, 

Tobacco, Firearms and Explosives 

(ATF), Department of Justice (DOJ), will 

submit the following information 

collection request to the Office of 

Management and Budget (OMB) for 

review and approval in accordance with 

the Paperwork Reduction Act of 1995. 

The proposed information collection 

(IC) is also being published to obtain 

comments from the public and affected 

agencies. 

DATES: Comments are encouraged and 

will be accepted for 60 days until June 

6, 2022. 

FOR FURTHER INFORMATION CONTACT: If 

you have additional comments 

regarding the estimated public burden 

or associated response time, 

suggestions, or need a copy of the 

proposed information collection 


khammond on DSKJM1Z7X2PROD with NOTICES